Aptalis Pharmaceutical Technologies (formerly Eurand) - Pharmaceutical Technologies for Optimal Drug Delivery Solutions White Papers

Alliance Management at Eurand - Principles and Practices for Driving Winning Partnerships Successful alliance management is a key indicator for top-performing pharmaceutical companies. Managing partnerships well is especially important for companies that devote significant resources to developing new products through collaboration. Eurand has a robust pipeline of such co-development partnerships and has devoted significant effort in recent years to ensuring our alliance management practices are best-in-class.
View white paper
Cyclobenzaprine ER: Development of the First Once-Daily Muscle Relaxant by Eurand Article chronicles current cyclobenzaprine products, including Eurand's development of the first and only Extended Release Cyclobenzaprine formulation. Cyclobenzaprine is the most-prescribed muscle relaxant in the US.
View white paper
Eurand: Research and Development Experts A wide range of capabilities and a unique business model has drawn talent to speciality pharmaceutical company Eurand.
View white paper
Solving Solubility: Eurand's Bioavailability Enhancement The insoluble nature of some compounds prevents the oral dosing of the treatments they enable. Innovation and precision engineering in equal measures have now overcome that problem, so that insolubility is no longer a barrier to oral delivery.
View white paper
The Potential of Drug Delivery Products in Emerging Markets (Article by Eurand) As economic, demographic and social changes sweep through the developing world, pharmaceutical companies are looking beyond the leading industrial nations to the growing potential of emerging markets. PriceWaterhouseCoopers estimates that the Gross Domestic Product of the E7 - the seven major emerging countries - will triple over the next decade, and by 2020 could account for close to 14 percent of a projected global pharmaceutical market of $800 billion.
View white paper